文献速递细菌感染、耐药与抗菌药物

仿制药上市对六国最后防线抗生素消费的影响

Impact of generic market entry on the consumption of last-resort antibiotics in six European countries.
PubMed 文献 · Clin Microbiol Infect · 2026-06-23

该回顾性多国分析利用IQVIA MIDAS数据,评估2012至2021年六种欧洲国家仿制药市场进入(GME)对达托霉素、利奈唑胺等抗生素消费的影响。结果显示GME影响因药物、国家和部门而异,达托霉素在所有国家医院消费显著上升,利奈唑胺在4国显著上升,而莫西沙星消费下降更多与欧洲药品管理局安全限制相关而非GME。

要点

  • 达托霉素GME后所有国家医院消费显著上升,中位率8.8至63.9 DDD/1000出院。
  • 利奈唑胺在4国医院消费显著上升,率24.7至110.4 DDD/1000出院。
  • GME是情境性风险因素,非抗生素使用增加的确定性驱动因素。

核心结论

  • GME未一致导致抗生素消费增加,但达托霉素和利奈唑胺GME后持续上升令人担忧。
  • 莫西沙星消费下降更多受欧洲药品管理局安全限制影响而非GME。

研究设计与样本

  • 回顾性多国分析,使用IQVIA MIDAS医院和零售消费面板数据(2012-2021年)。
  • 纳入奥地利、法国、德国、意大利、西班牙(医院和零售)及比利时(仅医院)。
  • 分析物质包括达托霉素、利奈唑胺、替加环素、替考拉宁和莫西沙星。

主要发现

  • GME影响因抗生素、国家和部门而异。
  • 达托霉素医院消费GME后所有国家显著增加,中位率从8.8至63.9 DDD/1000出院。
  • 利奈唑胺在4国显著上升,率24.7至110.4 DDD/1000出院。
  • 替加环素和替考拉宁模式异质。
  • 莫西沙星医院和零售消费主要呈下降趋势,但不一致显著,国家间差异明显。

临床怎么用

  • 对于最后防线抗生素,仿制药可及性可能削弱管理目标,需加强监测。
  • GME应视为情境性风险因素,而非处方增加的确定性驱动因素。
  • 强有力的监管干预可抵消GME后结构性成本效应等因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Excessive antibiotic use drives antimicrobial resistance. Patent expiry and subsequent generic market entry (GME) are suggested to alter antibiotic consumption, but evidence is limited. We examined GME impact on the use of selected antibiotics, including WHO 'Reserve' agents, in six European countries. METHODS: We conducted a retrospective multicountry analysis using IQVIA MIDAS data (hospital and retail consumption panels: Austria, France, Germany, Italy, Spain; Hospital consumption only: Belgium) from 2012 to 2021. Substances included daptomycin, linezolid, tigecycline, teicoplanin, and moxifloxacin. GME was defined in each country as the time of the first consumption of non-originator products. Hospital consumption was expressed in defined daily doses (DDDs) per 1000 discharges. Associations between GME and antibiotic use were assessed through segmented linear regression modelling. RESULTS: The impact of GME varied by antibiotic, country, and sector. Hospital consumption of daptomycin increased significantly following GME in all countries, with median rates from 8.8 to 63.9 DDD/1000 discharges. Linezolid use rose significantly in 4 countries, with rates between 24.7 and 110.4 DDD/1000 discharges. Tigecycline and teicoplanin showed heterogeneous patterns. By contrast, hospital and retail consumption of moxifloxacin showed predominantly decreasing trends, although not consistently significant, with marked country variation. CONCLUSIONS: GME did not consistently drive higher antibiotic consumption, whereas consumption trends were not fully explained by epidemiological factors or resistance patterns, either. The sustained post-GME rise in use of daptomycin and linezolid is concerning, given their reserve status, and suggests that for last-resort agents, generic availability may undermine stewardship objectives. In contrast, declines in moxifloxacin consumption appear more strongly influenced by European Medicines Agency safety restrictions than by GME. These findings indicate that GME constitutes a contextual risk factor rather than a deterministic driver of increased antibiotic use and demonstrate that robust regulatory interventions can counterbalance factors shaping prescribing patterns, including structural cost effects following GME.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Schweizer C, Weis S, Tacconelli E, et al. Impact of generic market entry on the consumption of last-resort antibiotics in six European countries. Clin Microbiol Infect. 2026. PMID: 42336237. doi:10.1016/j.cmi.2026.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。